Ys Biopharma Co, Stock Net Asset
| YSDelisted Stock | 0.48 0.03 5.88% |
YS Biopharma Co, fundamentals help investors to digest information that contributes to YS Biopharma's financial success or failures. It also enables traders to predict the movement of YS Biopharma Stock. The fundamental analysis module provides a way to measure YS Biopharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to YS Biopharma stock.
YS Biopharma |
YS Biopharma Co, Company Net Asset Analysis
YS Biopharma's Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Current YS Biopharma Net Asset | 1.72 B |
Most of YS Biopharma's fundamental indicators, such as Net Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, YS Biopharma Co, is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Net Asset is the value used in calculating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formula that uses closing prices of all positions in the fund's portfolio.
CompetitionBased on the recorded statements, YS Biopharma Co, has a Net Asset of 1.72 B. This is much higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The net asset for all United States stocks is notably lower than that of the firm.
YS Biopharma Net Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses YS Biopharma's direct or indirect competition against its Net Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of YS Biopharma could also be used in its relative valuation, which is a method of valuing YS Biopharma by comparing valuation metrics of similar companies.YS Biopharma is currently under evaluation in net asset category among its peers.
YS Biopharma Fundamentals
| Return On Equity | -0.78 | |||
| Return On Asset | -0.1 | |||
| Profit Margin | (0.67) % | |||
| Operating Margin | (0.49) % | |||
| Current Valuation | 429.47 M | |||
| Shares Outstanding | 188.33 M | |||
| Shares Owned By Insiders | 81.42 % | |||
| Shares Owned By Institutions | 2.85 % | |||
| Number Of Shares Shorted | 38.89 K | |||
| Price To Book | 2.10 X | |||
| Price To Sales | 0.29 X | |||
| Revenue | 687.2 M | |||
| EBITDA | (76.82 M) | |||
| Net Income | (145.48 M) | |||
| Total Debt | 498.63 M | |||
| Book Value Per Share | 5.10 X | |||
| Cash Flow From Operations | (182.47 M) | |||
| Short Ratio | 0.31 X | |||
| Earnings Per Share | (0.56) X | |||
| Target Price | 4.17 | |||
| Number Of Employees | 773 | |||
| Beta | 0.54 | |||
| Market Capitalization | 192.09 M | |||
| Total Asset | 1.72 B | |||
| Retained Earnings | (1.87 B) | |||
| Working Capital | 377.22 M | |||
| Net Asset | 1.72 B |
About YS Biopharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze YS Biopharma Co,'s financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of YS Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of YS Biopharma Co, based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Check out Your Current Watchlist to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Other Consideration for investing in YS Biopharma Stock
If you are still planning to invest in YS Biopharma Co, check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the YS Biopharma's history and understand the potential risks before investing.
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets |